ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryIndustryMedical Technology IndustryEpalingesHedera Dx SA
Hedera Dx SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Hedera Dx is the development and provision of liquid biopsy solutions for oncology, specifically NGS-based (Next-Generation Sequencing) solutions that can be processed in-house. The company aims to become a global provider of analytically and clinically validated liquid biopsy tests that are used in daily practice and comply with guidelines and regulatory-approved cancer treatment options.

AI-generated
Offering

Products & services

Industry:Medical Technology Industry
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Hedera Dx SA

12
NGS tumor profiling
NGS-based tumor profiling for FFPE, fresh tissue and blood samples; detection of SNVs, indels, CNVs, fusions, MSI and biomarkers for personalised therapies.
Liquid biopsy test panels
ctDNA-based liquid biopsy test panels for solid tumors; rapid NGS analysis, DNA-only workflow, detection of SNVs, indels, CNVs, fusions and MSI.
Hedera Profiling 1 test panels
115-gene panels for common solid tumors on FFPE and ctDNA samples; detection of SNVs, indels, CNVs, fusions and MSI with a DNA-only workflow.
Hedera Profiling 2 ctDNA test panel
32-gene ctDNA panel for common solid tumors such as lung, breast and colorectal; DNA-only liquid biopsy assay with rapid analysis and MSI detection.
Hedera Profiling 3 ctDNA test panel
43-gene ctDNA panel for common solid tumors such as lung, breast, ovary and prostate; DNA-only liquid biopsy assay with rapid reporting and MSI detection.
Hedera Profiling RNA test panel
43-gene RNA panel for solid tumors; detection of fusions, gene expression profiles, alternative splicing and exon-skipping-relevant variants.
Hedera Prime software analysis
Software for pathogenicity assessment, OncoKB-supported interpretation, therapy options in the report and customisable clinical reports.
Hedera Comply implementation program
IVDR implementation program with on-site training, wet-lab instruction, run assessment, software training, validation and technical support.
Real-World Evidence
Prospective real-world evidence studies with longitudinal clinical, molecular and patient-reported data for regulation, HTA, HEOR, biomarker research and study optimisation.
Bespoke Prospective RWE Studies
Tailored prospective RWE studies for specific evidence gaps in oncology; study design, patient selection, biomarker panels and endpoints according to partner needs.
Biopharma partnerships
Partnerships with biopharma for oncology research and development; decentralised tumor profiling, RWE datasets, companion diagnostic development and biomarker validation.
Sequencing Services
NGS-based sequencing services for tumor profiling and monitoring from tissue and liquid biopsy samples; supports clinical trials, biomarker stratification and longitudinal monitoring.
Trust & reputation

ranQ Trust Score of Hedera Dx SA: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Hedera Dx SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Hedera Dx SA scores 74.1 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.64.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Hedera Dx SA scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Hedera Dx SA scores 64.8 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.82.94%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.46.74%
Qualifications+0.00

Hedera Dx SA reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 27, 2025Media
Hedera Dx raises €15M to bring modern cancer care to patients worldwide
startupticker.ch
September 16, 2024Media
Positive clinical progress in the biotech scene
startupticker.ch
October 17, 2023Media
Hedera Dx Launches Blood Based Cancer Testing
startupticker.ch
September 21, 2022Media
€14 million to accelerate global adoption of liquid biopsies
startupticker.ch

Knowledge

No knowledge articles yet

Once Hedera Dx SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Hedera Dx SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Hedera Dx SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Hedera Dx SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hier entsteht die Karte
Route de la Corniche 5
1066 Epalinges
Opening hours
Mon
09:00 - 17:00
Tue
09:00 - 17:00
Wed
09:00 - 17:00
Thu
09:00 - 17:00
Fri
09:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-330.109.790
Founded
2021 · 5 years
Last commercial register change
February 18, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    LS
    LifeDX SA
    Epalinges
    NA
    Novigenix AI SA
    Epalinges
    BS
    BD Switzerland Sàrl
    Eysins
    AC
    ALDO CIVITILLO SA
    Lausanne
    ME
    Medtronic Europe Sàrl
    Tolochenaz
    MB
    Medtronic BioPharma Sàrl
    Tolochenaz
    CO
    Centre orthopédique Neuchâtel S.A., succursale de Payerne
    Payerne
    NL
    nardi lunetier sàrl
    Lonay